GNTA
NASDAQGenenta Science S.p.A.
Price$1.83-0.09 (-4.92%)
01:45 PM07:45 PM
News · 26 weeks29-50%
2025-12-142026-06-07
Mix2390d
- Insider12(52%)
- SEC Filings7(30%)
- Other4(17%)
Latest news
25 items- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Paracchi Pierluigi4 - Genenta Science S.p.A. (0001838716) (Issuer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- PRGenenta signs Definitive Agreements with Sophia High TechMILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has signed definitive agreements2 with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs. Genenta expects to fund a total of €6.0 million in two tranches. With the closing of the first tranche, Genenta will obtain a 19.9% stake, and with the closing of the second tranche, Genenta will own a 51% stake in Sòphia HT. The proceeds are expected to be deploy
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- INSIDERSEC Form 4 filed by Paracchi Giacomoantonio4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Galimi Francesco4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Mutti Miguel Maria4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Sharei Armon4 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 4 filed by Slansky Richard B4 - Genenta Science S.p.A. (0001838716) (Issuer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- PRGenenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programsMILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that it has entered into a binding offer with Sòphia High Tech S.r.l., (Sòphia HT) an Italian company manufacturing critical parts for Europe's space and defense programs, under which Genenta will fund Sòphia through two reserved capital increases, with the goal of reaching a controlling stake upon the achievement of defined performance milestones. The transaction with Sòphia High Tech would be completed in two phases and remains subject to
- INSIDERSEC Form 3 filed by new insider Paracchi Giacomoantonio3 - Genenta Science S.p.A. (0001838716) (Issuer)
- SECSEC Form 6-K filed by Genenta Science S.p.A.6-K - Genenta Science S.p.A. (0001838716) (Filer)
- PRGenenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi NaldiniMILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that, with respect to its biotechnology platform, Genenta has been and continues to be actively engaged with DC Advisory to explore potential collaboration opportunities for the further development of its original biotechnology platform, which originated from research conducted by founder-scientists, Professor Luigi Naldini and Bernhard Gentner. To date, DC Advisory has not identified, and the Company is not in any active discussions with,
- INSIDERSEC Form 3 filed by new insider Sharei Armon3 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mutti Miguel Maria3 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 3 filed by new insider Galimi Francesco3 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pierluigi Paracchi3 - Genenta Science S.p.A. (0001838716) (Issuer)
- INSIDERSEC Form 3 filed by new insider Slansky Richard B3 - Genenta Science S.p.A. (0001838716) (Issuer)
- PRGenenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia UniversityMILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) transforming to Saentra Forge (NASDAQ:SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that Pierluigi Paracchi, CEO of the Company, has been appointed as a member of the Board of Guarantors of the Italian Academy for Advanced Studies in America, the prestigious center for advanced scholarship hosted at Columbia University in New York, dedicated to promoting Italian culture, research, and intellectual exchange between Italy and the United States. The appointment was conferred by Deputy Prime Minister and Foreig
- PRGenenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation PlatformMILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies, today announced the appointment of Paolo Salvato to the Board of Directors of ATC, a manufacturer of tactical defense systems representing the Company's initial entry into defense technology manufacturing. The Company also provided an update on its ongoing evaluation of majority-control acquisition opportunities in regulated national-security sectors. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group
- SECSEC Form 424B5 filed by Genenta Science S.p.A.424B5 - Genenta Science S.p.A. (0001838716) (Filer)
GNTA FAQ
7 questionsWhat does Genenta Science S.p.A. do?
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in...Where does GNTA stock trade?
Genenta Science S.p.A. (GNTA) is listed on NASDAQ.What sector and industry is GNTA in?
Genenta Science S.p.A. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Genenta Science S.p.A. go public?
Genenta Science S.p.A. (GNTA) completed its IPO in 2021.What are analysts saying about GNTA?
Genenta Science S.p.A. has had 2 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $1500.00 price target on 2023-06-29. Recent price targets range from $1500.00 to $2500.00.What companies are similar to GNTA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare GNTA side-by-side with any of them on Quantisnow.How can I track GNTA on Quantisnow?
Quantisnow aggregates Genenta Science S.p.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GNTA to receive live email and push alerts on every new disclosure.